Impact of Vitamin D3 Administration on Cardiac Autonomic Tone in Asthma Chronic Obstructive Pulmonary Disease(COPD) Overlap Patients

Launched by BANGABANDHU SHEIKH MUJIB MEDICAL UNIVERSITY, DHAKA, BANGLADESH · Dec 11, 2018

Keywords

ClinConnect Summary

Previous studies reported earlier age of onset, symptom with longer duration, more exacerbation and devoid of adequate health care in Asthma Chronic Obstructive Pulmonary Disease (COPD) Overlap (ACO) patients compared to asthma and Chronic Obstructive Pulmonary Disease (COPD) alone. However their prevalence rate was reported between 15 and 55%. Existence of asthma and COPD has been reported in between 15-20% of patient. There is no population based data on ACO patients in Bangladesh. But one study very recently reported 11.6% of Asthma COPD Overlap (ACO) patients in this country. Thus it is...

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • • 40-80 years of age
• • Male
• • Middle class of socioeconomic condition:.
• • Stable patients of Asthma COPD Overlap (ACO) with \>4 years of disease duration.
• • Vitamin D deficient (Serum 25-hydroxycholecalciferol, 25(OH)D level \< 30 ng/ml).
• • Normal serum Ca+and inorganic phosphate level.
• • Hypertension with ACO.
• • Diabetes with ACO
• Exclusion Criteria:
• • Unstable patients with ACO (patients with exacerbation and medication changes in the past 30 days)
• • With acute exacerbation of any pulmonary diseases, such as,
• • Bronchial asthma
• • Acute respiratory tract infection
• • Current tuberculosis
• • Pleural effusion
• • Emphysematous bullae
• • Interstitial lung disease
• • Pneumonectomy or pulmonary lobectomy
• • Pulmonary fibrosis.
• • With acute exacerbation of any cardiac disease, like -
• • Unstable angina pectoris
• • Congestive heart failure
• • Myocardial infarction
• • Cardiac arrhythmia
• • Rheumatoid arthritis.
• • Inflammatory bowel disease.
• • Chronic Renal Failure.
• • Systemic lupus erythromatosIs.
• • Musculoskeletal diseases.
• • Any malignancy
• • Systemic hypertension
• • Use of drugs known to affect Central Nervous System (CNS) and vitamin D metabolism within 1 month prior to study, as,
• • Antiepileptics (Phenytoin, Carbamazepine)
• • Antibiotics (Clotrimazole, Rifampicin)
• • Antihypertensives (Nifedipine, Spironolactone)
• • Antiretroviral drugs (Ritononavir, Saquinavir)
• • Endocrine drugs (Cyproterone acetate)
• • Glucocorticoids
• • Bisphosphonate
• • Calcium supplement